BHB810
BigHat Biosciences: company profile
Phase 1/2 registry
Since , the date of the source that reports this phase.
Summary
BHB810 is a program from BigHat Biosciences. The source describes it as antibody-drug conjugate. It is being developed for CDH17-positive gastrointestinal cancers (gastric, gastroesophageal junction, colorectal, pancreatic). ClinicalTrials.gov lists it at Phase 1/2 (recruiting) under NCT07529808. The AI role named in the source is antibody design. Registry records: NCT07529808, Phase 1/2, recruiting, updated Oct 20, 2026. Dosing patients per post. The latest dated source is from Sep 24, 2026.
Built only from the sources listed on this page.
Facts
- Company
- BigHat Biosciences
- Indication
- CDH17-positive gastrointestinal cancers (gastric, gastroesophageal junction, colorectal, pancreatic)
- Therapeutic area
- Other
- Modality
- Antibody-drug conjugate
- AI role
- Antibody design
- Phase in the source
- Phase 1/2, as of Sep 24, 2026
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
Dosing patients per post
AI evidence
AI source: Company
“BHB810 was engineered using BigHat’s AI-powered antibody design platform”
Trial records
- NCT07529808 on ClinicalTrials.gov (opens in new tab) Phase 1/2 Recruiting Updated
Milestone timeline
-
ClinicalTrials.gov record: Phase 1/2
Dosing patients per post
-
Registry check
Registry Phase 1/2 vs post Phase 1.
-
NCT07529808 record updated
Phase 1/2, Recruiting
Spot an error? Tell me and I'll fix it.